TLR2 in other cancers


Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.
O'Neill LA, Bryant CE, Doyle SL.
Pharmacol Rev. 2009 Jun 61(2):177-97.

Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword.
Dajon M, Iribarren K, Cremer I.
Immunobiology. 2017 Jan;222(1):89-100.

Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling.
Yeh DW, Huang LR, Chen YW, Huang CF, Chuang TH.
J Immunol Res. 2016;2016:4368101.

Association of TLR2 and TLR4 Polymorphisms with Risk of Cancer: A Meta-Analysis.
Zhu L, Yuan H, Jiang T, Wang R, Ma H, Zhang S.
PLoS One. 2013 Dec 20;8(12)


Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer.
Grimmig T, Moench R, Kreckel J, Haack S, Rueckert F, Rehder R, Tripathi S, Ribas C, Chandraker A, Germer CT, Gasser M, Waaga-Gasser AM.
Int J Mol Sci. 2016 Dec 8;17(12).


Expression of toll-like receptors in hepatic cirrhosis and hepatocellular carcinoma.
Sun L, Dai JJ, Hu WF, Wang J.
Genet Mol Res. 2016 Jul 14;15(2).


Lung tumor exosomes induce a pro-inflammatory phenotype in mesenchymal stem cells via NFκB-TLR signalling pathway.
Li X, Wang S, Zhu R, Li H, Han Q, Zhao RC.
J Hematol Oncol. 2016 Apr 18;9:42.


Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways.
Echizen K, Hirose O, Maeda Y, Oshima M.
Cancer Sci. 2016 Apr;107(4):391-7.


Toll-like receptor signaling in colorectal cancer: Carcinogenesis to cancer therapy.
Li TT, Ogino S, Qian ZR.
World J Gastroenterol. 2014 Dec 21;20(47):17699-17708.


Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice
Yan J, Hua F, Liu HZ, Yang HZ, Hu ZW.
Acta Pharmacol Sin. 2012 Apr;33(4):503-12

Blocking TLR2 activity attenuates pulmonary metastases of tumor.
Yang HZ, Cui B, Liu HZ, Mi S, Yan J, Yan HM, Hua F, Lin H, Cai WF, Xie WJ, Lv XX, Wang XX, Xin BM, Zhan QM, Hu ZW.
PLoS One. 2009 4(8):e6520.


Toll-like receptors and prostate cancer.
Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D.
Front Immunol. 2014 Jul 23;5:352.


TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.
Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin G, Squillace L, Gurrea Soteras M, Aldo P, Mor G.
Cell Cycle. 2013 Feb 1;12(3):511-21.

Role of Toll-like receptors in cervical, endometrial and ovarian cancers: A review.
Husseinzadeh N, Davenport SM.
Gynecol Oncol. 2014 Nov;135(2):359-363.


Role of TLR2-dependent inflammation in metastatic progression.
Kim S, Karin M.
Ann N Y Acad Sci. 2011 Jan 1217:191-206.

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis.
Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M.
Nature. 2009 Jan 1;457(7225):102-6.